<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[eli lilly Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/eli+lilly.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to eli lilly]]></description>
	<s:counts start="0" returned="20" found="1338" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Oral-lyn vs. Afresa: How Generex Will Beat Mannkind]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174252-oral-lyn-vs-afresa-how-generex-will-beat-mannkind%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[R.J Steffens submits: As biotech companies and large pharma embark on paths to usher in more effective diabetes drugs to market, one of the more significant concerns regarding diabetes related drug development is safety. The FDA has increasingly issued new alerts from previously approved drugs such as GlaxoSmithKline's GSK Avandia,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 19 Nov 2009 04:19:20 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/r.j+steffens.html"><![CDATA[R.J Steffens]]></category>
		<category domain="http://resources.bnet.com/topic/generex+biotechnology+corp..html"><![CDATA[Generex Biotechnology Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/mannkind+corp..html"><![CDATA[MannKind Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GNBT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MNKD</category>
		<category domain="tickers">GNBT,MNKD</category>
	</item>
	<item>
		<title><![CDATA[FDA tackles gray area of social media]]></title>
		<link><![CDATA[http://industry.bnet.com/technology/news-analysis/fda-tackles-gray-social-media/20355/]]></link>
		<description><![CDATA[By Deepa Seetharaman WASHINGTON (<a href="http://resources.bnet.com/index.php?source=Reuters">Reuters</a>)- Drug makers, Internet companies and nonprofits called for clarity on what is a gray area for U.S. health regulators: how drug promotion on Twitter, Wikipedia, blogs and other social media can be regulated. The two-day Food and Drug Administration hearing aims to find out if...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Fri, 13 Nov 2009 13:34:04 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advertisement.html"><![CDATA[Advertisement]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/twitter+inc..html"><![CDATA[Twitter Inc.]]></category>
	</item>
	<item>
		<title><![CDATA[paidContent Quick Hits 11.12.09]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fpaidcontent.org%2Farticle%2F419-paidcontent-quick-hits-11.12.09%2F&siteid=23&tag=contentnext]]></link>
		<description><![CDATA[ »  GameStop is making digital download add-ons of game purchases a big part of its future. [Variety]»  Pharmaceutical giants like Eli Lilly and Pfizer want to expand their online presence, but need the FDA to set some rules down first. [WSJ]»  The NFL is very happy with its TV...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 12 Nov 2009 20:38:30 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/advertising+%2526+promotion.html"><![CDATA[Advertising & Promotion]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/features.html"><![CDATA[Features]]></category>
		<category domain="http://resources.bnet.com/topic/quick+hits.html"><![CDATA[Quick Hits]]></category>
		<category domain="http://resources.bnet.com/topic/alex+ferreyra.html"><![CDATA[Alex Ferreyra]]></category>
	</item>
	<item>
		<title><![CDATA[U.S. FDA tackles gray area of social media]]></title>
		<link><![CDATA[http://industry.bnet.com/technology/news-analysis/fda-tackles-gray-social-media/20158/]]></link>
		<description><![CDATA[By Deepa Seetharaman WASHINGTON (<a href="http://resources.bnet.com/index.php?source=Reuters">Reuters</a>)- Drug makers, Internet companies and nonprofits packed a hearing into what is a gray area for U.S. health regulators: how far Twitter, Wikipedia, blogs and other social media can go in promoting drugs. The two-day public hearing, convened Thursday by the Food and Drug Administration,...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Thu, 12 Nov 2009 11:21:53 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
	</item>
	<item>
		<title><![CDATA[Biotech Blooms at Eli Lilly]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F172104-biotech-blooms-at-eli-lilly%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[The Burrill Report submits:  Pharmaceutical giant Eli Lilly LLY opened a new state-of-the-art biotechnology center in San Diego, part of an ongoing effort by the drugmaker to transform itself into a biotech titan. The move follows a relocation of its ImClone headquarters to a new biopharmaceutical research cluster in...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 08 Nov 2009 08:14:24 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/the+burrill+report.html"><![CDATA[The Burrill Report]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[Ask Your Doctor If This Ad Is Right for You]]></title>
		<link><![CDATA[http://industry.bnet.com/technology/news-analysis/doctor-ad/19213/]]></link>
		<description><![CDATA[By Arlene Weintraub Does it seem like you hear the phrase "ask your doctor" every time you turn on the TV? There's a reason. Drug companies spend about $5 billion a year in the U.S. on ads imploring people to talk to their physicians if they think a pill they've...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Thu, 05 Nov 2009 13:52:09 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advertisement.html"><![CDATA[Advertisement]]></category>
	</item>
	<item>
		<title><![CDATA[Lilly Hopes New San Diego Facility Will Be 'a Biotechnology Powerhouse']]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F170348-lilly-hopes-new-san-diego-facility-will-be-a-biotechnology-powerhouse%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[The Burrill Report submits:  Pharmaceutical giant Eli Lilly LLY opened a new state-of-the-art biotechnology center in San Diego, part of an ongoing effort by the drugmaker to transform itself into a biotech titan. The move follows a relocation of its Imclone headquarters to a new biopharmaceutical research cluster in...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 01 Nov 2009 01:12:13 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/the+burrill+report.html"><![CDATA[The Burrill Report]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[AstraZeneca to Pay $520 Million to Settle Four Seroquel Cases - NYT]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/astrazeneca-pay-520-million-settle/18364/]]></link>
		<description><![CDATA[    The pharmaceutical company  AstraZeneca  said Thursday that it had reached a $520 million agreement to settle two federal investigations and two whistle-blower lawsuits over the sale and marketing of its blockbuster psychiatric drug Seroquel.    One of the investigations related to "selected...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Fri, 30 Oct 2009 14:00:43 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/astrazeneca+plc..html"><![CDATA[AstraZeneca Plc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
		<category domain="tickers">AZN</category>
	</item>
	<item>
		<title><![CDATA[Eli Lilly and Company Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-354840.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator Operator Instructions Your first question comes from John Boris - Citi. John Boris - Citi First question just has to do with the revised guidance. If I just take the midpoint of that range and assign a 10% or 15% growth rate to that, coming up...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Wed, 21 Oct 2009 11:12:09 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[Eli Lilly Q3: Beats Estimates, Raises Guidance]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F167866-eli-lilly-q3-beats-estimates-raises-guidance%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Wednesday, Eli Lilly & Co. LLY reported strong third quarter financials. The company&#8217;s earnings per share of $1.20 surpassed the Zacks Consensus Estimate of $1.02 and 98 cents reported in the year-ago period. Revenues recorded a 7% year on year increase to $5.56 billion, driven by...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 21 Oct 2009 08:17:56 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[Lilly Profit Tops Estimates on Drug Sales, Taxes]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/lilly-profit-tops-estimates-drug/16787/]]></link>
		<description><![CDATA[By Lewis Krauskopf NEW YORK (<a href="http://resources.bnet.com/index.php?source=Reuters">Reuters</a>) - Eli Lilly and Co LLY posted third-quarter profit well above Wall Street expectations on Wednesday on strong performance of its major prescription drugs and lower taxes, sending shares up 1.9 percent. Sales of lung cancer treatment Alimta, anti-depressant Cymbalta, Humalog insulin and schizophrenia...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Wed, 21 Oct 2009 07:47:55 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/thomson+reuters+corp..html"><![CDATA[Thomson Reuters Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[sales]]></category>
		<category domain="http://resources.bnet.com/topic/analyst.html"><![CDATA[Analyst]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[Stock Futures Dip; Raft of Earnings Eyed]]></title>
		<link><![CDATA[http://industry.bnet.com/financial-services/news-analysis/stock-futures-dip-raft-earnings/16748/]]></link>
		<description><![CDATA[(<a href="http://resources.bnet.com/index.php?source=Reuters">Reuters</a>) - U.S. stock index futures pointed to a lower open on Wall Street on Wednesday, with futures for the S&P 500 down 0.24 percent, Dow Jones futures down 0.1 percent and Nasdaq 100 futures down 0.34 percent. Yahoo Inc YHOO will be in focus after the company beat Wall...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Wed, 21 Oct 2009 03:17:55 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/wall+street.html"><![CDATA[Wall Street]]></category>
		<category domain="http://resources.bnet.com/topic/stock.html"><![CDATA[Stock]]></category>
		<category domain="http://resources.bnet.com/topic/yahoo%2521+inc..html"><![CDATA[Yahoo! Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fdic.html"><![CDATA[FDIC]]></category>
		<category domain="http://resources.bnet.com/topic/dow+jones+%2526+company+inc..html"><![CDATA[Dow Jones & Company Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DJ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">YHOO</category>
		<category domain="tickers">DJ,YHOO</category>
	</item>
	<item>
		<title><![CDATA[Merck pays $3m in speaker fees to US doctors]]></title>
		<link><![CDATA[http://industry.bnet.com/healthcare/news-analysis/merck-pays-3m-speaker-fees/16714/]]></link>
		<description><![CDATA[Merck paid more than $3m in speaker fees to US doctors during the second quarter of this year, according to figures from the company that represent a step towards greater transparency in the New Jersey-based pharmaceutical group's commercial links with prescribers. The company has provided less information, however, than Eli...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Tue, 20 Oct 2009 20:22:43 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">LLY,MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck reveals doctors' speaker fees after calls for transparency]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2F69646776-bdd9-11de-9f6a-00144feab49a.html&siteid=23&tag=financialtimes]]></link>
		<description><![CDATA[ Merck paid more than $3m in speaker fees to US doctors during the second quarter of this year, according to figures from the company that represent a step towards greater transparency in the commercial links of the New Jersey-based pharmaceutical group with prescribers.The company has provided less information, however,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 20 Oct 2009 19:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/payment.html"><![CDATA[Payment]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/company+news.html"><![CDATA[Company News]]></category>
		<category domain="http://resources.bnet.com/topic/general+news.html"><![CDATA[General News]]></category>
		<category domain="http://resources.bnet.com/topic/health+%2526+healthcare.html"><![CDATA[Health & Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/financial+times.html"><![CDATA[Financial Times]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">LLY,MRK</category>
	</item>
	<item>
		<title><![CDATA[Lilly's promo deal with CVS draws fire]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/lillys-promo-cvs-draws-fire/16386/]]></link>
		<description><![CDATA[Eli Lilly is catching heat for paying CVS Caremark to promote its Cymbalta drug to doctors. The CVS pharmacy benefits manager has been sending promotional materials to doctors, touting Cymbalta for its new indication as a fibromyalgia treatment. The promos come under the guise of professional advice--"We are committed to...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Mon, 19 Oct 2009 12:14:06 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/caremark+inc..html"><![CDATA[Caremark Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/cvs+corp..html"><![CDATA[CVS Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CVS</category>
		<category domain="tickers">CVS</category>
	</item>
	<item>
		<title><![CDATA[Lilly offloads 700-worker Indiana plant]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/lilly-offloads-700-worker-indiana/15967/]]></link>
		<description><![CDATA[The folks in Lafayette, IN, are hailing drugmaker Eli Lilly right now. Rather than closing a manufacturing plant there as planned, the drugmaker found a buyer, saving some 700 jobs.Â "We're very, very excited and pleased with this," John Lechleiter photo, Lilly's chairman and CEO, told the Indianapolis Star. "I think...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Thu, 15 Oct 2009 09:21:53 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/employee.html"><![CDATA[employee]]></category>
		<category domain="http://resources.bnet.com/topic/api.html"><![CDATA[API]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[Pfizer Suspends Lung Cancer Study]]></title>
		<link><![CDATA[http://industry.bnet.com/healthcare/news-analysis/pfizer-suspends-lung-cancer-study/15170/]]></link>
		<description><![CDATA[Pfizer has stopped entering new patients into the most advanced clinical trial of its experimental lung cancer drug because those who received it were more likely to suffer serious side effects and die. The conclusions are not definitive. Patients enrolled in the study will continue to get the drug, figitumumab....]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Fri, 09 Oct 2009 12:22:54 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/roche+holding+ag.html"><![CDATA[Roche Holding AG]]></category>
		<category domain="http://resources.bnet.com/topic/news.html"><![CDATA[News]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[As Lilly Axes 5,500 Jobs It Adds 2,000 More in China]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004674/as-lilly-axes-5500-jobs-it-adds-2000-more-in-china/]]></link>
		<description><![CDATA[The 5,500 people about to lose their jobs at Eli Lilly might be wondering where they can get new posts. One option: China. Even as Lilly wields the ax at reps in the U.S., it is doubling its sales force in the East. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 07 Oct 2009 14:44:16 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/job.html"><![CDATA[Job]]></category>
		<category domain="http://resources.bnet.com/topic/recruitment+%2526+selection.html"><![CDATA[Recruitment & Selection]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[U.K. activists assail antipsychotic "abuse"]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/uk-activists-assail-antipsychotic-abuse/14724/]]></link>
		<description><![CDATA[Patient advocates in Britain are fighting back against overuse of antipsychotic drugs in the elderly, citing new research showing just how widespread that use is. They're calling on the U.K. government to publish its review of antipsychotic use, which has been overdue since May. Three-quarters of hospital nurses have seen...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Wed, 07 Oct 2009 09:17:41 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
	</item>
	<item>
		<title><![CDATA[Eli Lilly to Double China Workforce]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F164438-eli-lilly-to-double-china-workforce%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Eli Lilly (NYSE: LLY) plans to double its workforce inside of China this year, bringing the total up to 2,000. At the same time, the company announced a 5,500 employee reduction in its worldwide staff count that will help trim $1 billion in annual costs. Inside...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 02 Oct 2009 12:51:23 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
</channel>
</rss>
